Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio(Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 2:00 PM ET.
The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through virtualinvestorco.com/asktheceo-pali. Participating companies will answer as many questions as possible during the event.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.palisadebio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.48 |
| Daily Change: | 0.05 3.50 |
| Daily Volume: | 438,571 |
| Market Cap: | US$4.100M |
January 22, 2025 January 16, 2025 December 13, 2024 November 21, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
